<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390568</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0043</org_study_id>
    <nct_id>NCT04390568</nct_id>
  </id_info>
  <brief_title>A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body</brief_title>
  <official_title>An Open-label Phase I Trial to Assess Pharmacokinetics and Safety of Single Subcutaneous Doses and Single Intravenous Doses of BI 655130 in Healthy Chinese Male and Female Subjects (Single Doses, Open-label Study in Parallel-group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate pharmacokinetics, including dose
      proportionality, following single intravenous and subcutaneous doses of spesolimab in healthy
      Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0 to infinity of spesolimab</measure>
    <time_frame>Up to 179 days</time_frame>
    <description>Area under the concentration-time curve of spesolimab in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of spesolimab</measure>
    <time_frame>Up to 179 days</time_frame>
    <description>Maximum measured concentration of spesolimab in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment-emergent adverse events (AEs)</measure>
    <time_frame>Up to 179 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of drug-related adverse events (AEs)</measure>
    <time_frame>Up to 179 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655130</intervention_name>
    <description>BI 655130</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_label>Dose group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects (at least three subjects for each gender within each
             dose group) according to the assessment of the investigator, as based on a complete
             medical history including a physical examination, vital signs (blood pressure (BP),
             pulse rate (PR), respiratory rate (RR), body temperature), 12-lead ECG, and clinical
             laboratory tests.

          -  Chinese ethnicity, according to the following criteria: Ethnic Chinese, born in China
             and have 4 ethnic grandparents who were all born in China

          -  Age of 18 to 45 years (inclusive)

          -  Body weight ≥50 kg for male and ≥45 kg for female with body mass index (BMI) range ≥19
             and &lt; 26 kg/m2 at visit 1

          -  Signed and dated written informed consent prior to admission to the trial, in
             accordance with GCP and local legislation

          -  Female subjects who meet any of the following criteria from at least 30 days before
             the first administration of trial medication until 16 weeks after trial completion
             [c03320877-06]:

               -  Women of childbearing potential (WOCBP)1 must be ready and able to use highly
                  effective methods of birth control per ICH M3 (R2) that result in a low failure
                  rate of less than 1% per year when used consistently and correctly. A list of
                  contraception methods meeting these criteria is provided in the subject
                  information

               -  A vasectomised sexual partner (vasectomy at least one year prior to enrolment)

               -  Surgically sterilised (including hysterectomy)

               -  Postmenopausal, defined as at least one year of spontaneous amenorrhoea (in
                  questionable cases a blood sample with simultaneous levels of
                  follicle-stimulating hormone (FSH) above 40 U/L and estradiol below 30 mg/L is
                  confirmatory)

        Exclusion Criteria:

          -  Major surgery (major according to the investigator's assessment) performed within 12
             weeks prior to treatment or planned within 12 months after screening, e.g. hip
             replacement

          -  Any finding in the medical examination (including BP, PR, RR, Body temperature or
             12-lead ECG) deviating from normal and assessed as clinically relevant by the
             investigator

          -  Repeated measurement of systolic BP outside the range of 90 to 140 mmHg, diastolic BP
             outside the range of 50 to 90 mmHg, or PR outside the range of 50 to 90 bpm

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Any evidence of a concomitant disease assessed as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders. Diseases of the central nervous system (including
             but not limited to any kind of seizures or stroke), and other relevant neurological or
             psychiatric disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections including active and latent tuberculosis, human
             immunodeficiency virus (HIV) or viral hepatitis; QuantiFERON tuberculosis (TB) test
             will be performed at screening Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Zhang</last_name>
      <phone>13816357098</phone>
      <email>zhangj_fudan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

